EnginZyme AB

Our direct competitors are companies using synthetic biotechnology to develop manufacturing processes, such as Gingko, Genomatica, Solugen, etc.

- We differentiate from companies that rely on cell based processes as we are using enzymes, which enables faster, simpler and more robust process development. Cell based technologies are more complex and difficult to scale-up due to the sensitivity of living organisms (toxicity, low productivity and cell debris leading to costly purification, inhomogeneous, large and complex reactors,...).

- Companies using enzymes in their development need to circumvent some challenges that EnginZyme is solving. Our key strength is the utilisation of immobilised enzymes to develop high performance biocatalysts with long lifetime and high productivity. We are able to develop novel and bespoke solutions as our capabilities range from enzyme engineering & development, biocatalyst development to process development and piloting of manufacturing processes.

We generate revenues through customer driven projects and internal projects. We develop new manufacturing processes that we can commercialize as:
1- catalyst supply to manufacturing partner or customer,
2- process license,
3- production & marketing of chemicals (under a JV with partner, own production unit or contract manufacturing)

We have a portfolio of patents granted globally for our basic EziG technology, covering general enzyme immobilisations and their use in production processes. Our proprietary immobilisation technology eliminates several common issues with enzyme immobilisation and is broadly applicable, demonstrated by successful immobilisation and utilisation of all enzyme classes.

We are currently developing several solutions across market verticals:
- Edible oil processing: we are creating a biocatalyst outperforming incumbent one, currently scaling up and ready for industrial use in Q3/2024 with our codevelopment customer
- Enzymatic processes to improve existing sweeteners production or develop new sweeteners: we piloted the process and we are launching a dedicated spinout to obtain food approvals and commercial launch of kojibiose (prebiotic low calorie sweetener)
- We are developing a process to produce high value intermediates for mRNA vaccines
- We developed a process and produced samples for alpha-arbutin, a cosmetic ingredient. We are looking for off-takers and process licensees

Many green chemistry companies have biomimetic processes — imitating what nature does. In nature enzymes are the key catalysts that allow cells to create chemicals necessary for life. But using living cells to manufacture chemicals industrially can be complex and requires a highly conditioned environment known as a bioreactor. EnginZyme enables cell-free processes in equipment already established in the industry, avoiding high CapEx. Additionally, EnginZyme’s tailored, stable, solid biocatalysts can be used both as a standard heterogeneous catalyst in batch and in continuous processes, therefore enabling more productive and efficient manufacturing. Furthermore, EnginZyme does not only focus on the performance of the catalyst. Instead we evaluate and design a complete process solution from raw materials to products. By designing with the end commercial solution in mind, the scale-up is faster and risks are mitigated. In every new project we perform techno economic assessments, analysing the economic performance of proposed industrial process or product to ensure we met set cost targets.
We are developing processes & products in several markets as we have a versatile technology (food, nutraceuticals, cosmetics, chemical intermediates, APIs, etc)